Abstract: The invention concerns a detecting apparatus (12) comprising:—at least two sensors (24, 26, 28), with at least one sensor (24) being an ultrasound transducer adapted to produce ultrasound waves, and—a positioning device (16) defining several compartments (22), each compartment (22) being adapted to hold a sensor (24, 26, 28) and each compartment (22) being located at predetermined location, the positioning device (16) comprising a holder adapted to be fixed on the skull of a subject, the positioning device (16) being adapted to be maintained on the head of the subject using the holder.

Abstract: The invention relates to an electrically insulating composite material (1) comprising a polyepoxide matrix (2) of cycloaliphatic type or of diglycidyl ether type in a content of less than 40% by mass, from 20 to 75% by mass of one or several micrometric and/or mesometric filler(s) (3), and from 0.1 to 20% by mass of at least one ionic liquid (4), the masses being expressed relative to the total mass of the electrically insulating composite material (1). The invention also relates to a method for manufacturing such an electrically insulating composite material (1), as well as its use for an electrically insulating support (9) in a metal-enclosed substation (5).

Abstract: The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.

Abstract: Evaluation of the perception of colors by mammals with a view to obtaining a characteristic biomarker of each tested subject takes advantage of the slow pupillary oscillatory response to generate an objective neurological signature of this perception of colors. A method based on pupil frequency tagging is used at a tagging frequency Ftag adapted to the pupil response speed. A dynamic two-color stimulus is displayed, this stimulus comprising a two-color pattern the colors of which are inverted at the frequency Ftag, one of the colors gradually varying in a range of possible values. From the pupillary response, a signal representative of the oscillation power of the pupil is generated. The minimum of this signal corresponds to the relative iso-luminance of the tested pair of colors.

Abstract: A method for determining a configuration setting of a source of ionizing radiation reducing a radiation dose absorbed by a patient and a practitioner in a medical operating room during a procedure. Prior to the procedure a database of maps of simulated propagation and scattering of ionizing radiation in a model of the medical operating room is obtained for different configuration settings. During the procedure, a position of the practitioner is determined. After determining a set of configuration settings of the source enabling the production of an image of a target anatomical structure a radiation dose absorbed by the patient and the practitioner is determined using the maps from the database. A recommended configuration setting for which a combined radiation dose is reduced is then outputted.

Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.

Abstract: The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: A positive electrode active material for a sodium-ion battery has the following formula: NaxNi0.5-yCuyMn0.5-zTizO2, in which: -x varies from 0.9 to 1; -y varies from 0.05 to 0.1; -z varies from 0.1 to 0.3. When z is equal to 0.1 and x is equal to 1, then y is not equal to 0.05.

Abstract: The present invention particularly relates to a method for physical vacuum deposition of a coating (R) comprising at least one material (M) on at least a portion of a front face (10) of a support (1), said at least one material (M) originating from an evaporation source or an atomisation source (2), wherein:—use is made of a support (1), at least a portion of the front face (10) of which is smooth, that is to say, does not have any roughness and/or reliefs and/or recesses;—said vacuum deposition is carried out while varying the thickness distribution of the material (M) on said front face (10), that is, while progressively varying the thickness deposited, from a central region (11) in the direction of at least one lateral region (12) contiguous to the central region (11), without modifying the position of the evaporation source or atomisation source (2) of the material particles (M).

Abstract: The present invention is directed to novel compounds of Formula (I): pharmaceutically acceptable salts or solvates thereof, and their use, in particular in the treatment or prevention of malaria.

Abstract: The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

Abstract: The present invention relates to hydrogels prepared using silylated organic molecules (such as silylated biomolecules), a process for obtaining the same, and uses thereof.

Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.

Abstract: The invention relates to a method for labeling specifically living bacteria, comprising the steps of: a) incubating said bacteria of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into the envelope of such bacteria, and b) contacting said modified monosaccharide residue incorporated within the envelope of the bacteria with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group with said second reactive group, characterized in that said modified monosaccharide compound has the following formula (I), or a salt thereof: Wherein —A, B and C can be independently H, OH, NH2, OH and NH2 being substituted or not by protecting groups thereof and —D is an alkyl chain in C2 to C4, each carbon being substituted or not by OH or NH2, OH and NH2 being substituted or not b

Abstract: Disclosed is a method for fabricating coils including the steps of providing a liquid droplet having a diameter on length-scales ranging from hundreds of micrometers to nanometers and bringing a fiber into contact with the liquid droplet, wherein the radius of the liquid droplet is sufficiently high in comparison to the bending elastocapillary length which is defined as where E is the Young's modulus of the elastic fiber, r is the radius of the fiber and ? is the interfacial tension between the droplet and surrounding medium, so that capillary forces induce the spontaneous winding of the fiber around the droplet, to fabricate a coil with a diameter in the range from hundreds of micrometers to nanometers. Also disclosed is a system for making microcoils and to the product thereof.

Abstract: The present invention relates to a method for ex vivo generating and expanding ?? Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR?? unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR?? unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR??+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo ?? Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR??+ Foxp3+.

Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the model in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.

Abstract: The invention relates to an active pharmaceutical ingredient consisting exclusively of the combination of (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and of methyl (2S,3E,4S)-4-{2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(?-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a drug or veterinary product, particularly in the prevention and/or treatment of pathological disorders of carbohydrate and/or lipid metabolism.

Abstract: The present invention relates to a tourniquet (1) comprising: • a support (2) for surrounding a first portion of a limb, • an elastic sleeve (4) to be held in a stretched position around the support (2), the support (2) preventing contraction of the elastic sleeve (4), • a grip element (8) which is movable relative to the support (2), • a drive element (6) for driving the elastic sleeve (4), when the grip element (8) is moved manually relative to the support (2), from its stretched position around the support to a blood vessel constricting position wherein the elastic sleeve (4) surrounds a second portion of the limb, adjacent to the first portion of the limb but not surrounded by the support (2), in such a way that the elastic sleeve (4) can contract by resilient return, and thus compress the second portion of the limb.